plc, of Dublin, Ireland, bought into the respiratory franchise shared by Theravance Inc., of South San Francisco, and London-based Glaxosmithkline plc (GSK), acquiring for $1 billion a 21 percent stake in Theravance's future royalty streams from four drugs that are partnered with GSK. (See BioWorld Today, May 14, 2013.) One of the compounds in the deal, Breo (fluticasone furoate and vilanterol inhalation powder), which is administered using the Ellipta inhaler, recently won FDA approval as a

San Francisco; PTLA)7 4/12/13 5/22/13 8.42S $14.50 33.9 Morgan Stanley Credit Suisse (co-lead) Cowen & Co...FILED AND PENDING Company (Symbol)#* Date Filed Shares/Units (M) Price Shares Out Lead, Other Underwriters Gross (US$M) INITIAL OFFERINGS Audeo Oncology Inc. (San Francisco; AURX)1 7/6/12 3.25S $14-$16 10.8 Leerink Swann Oppenheimer & Co. (co-lead) $49 Bluebird Bio Inc. (Cambridge, Mass.; BLUE)2 5/14/13 5S $14-$16 21.9 J.P. Morgan BofA Merrill Lynch (co-lead) Cowen & Co

launch of Xofigo injection to treat castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease 5/31/13 Curis Inc. (Lexington, Mass.) Genentech Inc. (South San Francisco; unit of Roche AG) $4 For the Australian approval of Erivedge (vismodegib) for metastatic basal cell carcinoma, or locally advanced basal cell carcinoma where surgery and/or radiation therapy are not appropriate 5/13/13 Isis Pharmaceuticals Inc. (Carlsbad, Calif.) Biogen Idec Inc

The Angeles Clinic and Research Institute presented results for MPDL3280A, a cancer candidate by Genentech Inc., of South San Francisco

through various stages of preclinical evaluation," said Sean McCarthy, CEO of South San Francisco-based CytomX

Johnson & Johnson, of New Brunswick, N.J., said its Johnson & Johnson Innovation arm signed an agreement with the California Institute for Quantitative Biosciences (QB3) to allocate 5,000 square feet of the space in QB3's new 24,000-square foot biosciences incubator in San Francisco

An example of the process: PEP02, a nano-liposomal formulation of cancer drug irinotecan, licensed in 2003 from Hermes BioSciences, of San Francisco

It works, but maybe not as well as AstraZeneca had hoped, in terms of having a robust bone benefit, in particular," said Raul Rodriguez, president and chief operating officer for South San Francisco-based Rigel

Tunitas Therapeutics Inc., of San Francisco, was awarded a Small Business Innovation Research Phase II grant from the National Institute of Allergy and Infectious Disease

Bayer HealthCare Pharmaceuticals, of Wayne, N.J., and Onyx Pharmaceuticals Inc., of South San Francisco, reported positive results from the Phase III DECISION trial investigating Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer

Hyperion Therapeutics Inc., of South San Francisco, said it completed the acquisition of Buphenyl (sodium phenylbutyrate) tablets and powder, from Ucyclyd Pharma Inc., a subsidiary of Valeant Pharmaceuticals International Inc., of Laval, Quebec, Buphenyl is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders (UCD...Onyx Pharmaceuticals Inc., of South San Francisco, and the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive

the second award of £800,000 is to fund preclinical development of ReN003 for treating retinitis pigmentosa 3/12/13 APRIL Armgo Pharma Inc. (Tarrytown, N.Y.) Muscular Dystrophy Association $1 Grant For preclinical work in support of an investigational new drug application for AMR201, which has the potential to treat Duchenne's muscular dystrophy 4/18/13 Cytokinetics Inc. (South San Francisco) Families of Spinal Muscular Atrophy ND Award To support preclinical research on muscle function in a

Exelixis Inc., of South San Francisco, started METEOR, a Phase III pivotal trial comparing cabozantinib to everolimus (Afinitor, Novartis) in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor

Alios BioPharma Inc., of South San Francisco, began oral dosing of ALS-8176 in a Phase I trial...Sunesis Pharmaceuticals Inc., of South San Francisco, published a paper in the July 2013 issue of Expert Opinion on Pharmacotherapy detailing the advantages of voxaroxin over anthracycline therapy

Pfizer Inc., of New York, said its Centers for Therapeutic Innovation (CTI) has expanded into the development of small-molecule drug candidates through a partnership with the University of California, San Francisco (UCSF

The Royalty offer was contingent on Elan's shareholders voting down all of its M&A transactions, including its recent $1 billion cash deal to buy a 21 percent stake in South San Francisco-based Theravance Inc.'s future royalty stream from the respiratory franchise it shares with London-based GlaxoSmithKline plc

Net proceeds of the offering, set to close May 31, will be deposited into escrow pending the closing of Elan's previously announced royalty participation transaction with South San Francisco-based Theravance Inc

Medivation Inc., of San Francisco, said partner Astellas Pharma Inc., of Tokyo, submitted an application for marketing approval in Japan for enzalutamide in prostate cancer

That's where we think the future will be." – Trevor Hallam, chief scientific officer of San Francisco-based antibody-drug conjugate developer Sutro Biopharma Inc., discussing the Phase III failure of Pfizer Inc.'s ADC inotuzumab ozogamicin in non-Hodgkin's lymphoma "A good drug without a good management team doesn't optimally get to market." – Deepa Pakianathan, general partner, Delphi Ventures, a participant in the Series B financing of Karyopharm Therapeutics Inc